García García Yolanda, Marín Alcalá Maria, Martínez Vila Clara
Medical Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí, I3PT. Universitat Autònoma de Barcelona, Parc Taulí 1, Sabadell, 08208, Barcelona, Spain.
EJC Suppl. 2020 Aug 22;15:77-86. doi: 10.1016/j.ejcsup.2020.02.003. eCollection 2020 Aug.
Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).
血管生成是癌症的一个已知标志，在卵巢癌的发生和侵袭中起着关键作用。抗血管生成药物在卵巢癌治疗中作为单一疗法或与化疗、免疫疗法或聚ADP核糖聚合酶（PARP）抑制剂联合使用时具有活性。我们综述了在卵巢癌治疗方案（新辅助治疗、一线治疗和复发治疗）中实际应用或当前正在评估的最重要药物的作用机制、临床活性和安全性。
